HILO Corporation

Horizon IlluminationLab is a university-launched startup focused on the social implementation of advanced bioimaging technology developed by Professor Yusuke Ohba from Hokkaido University. The company specializes in using fluorescent bioimaging to evaluate the efficacy of drugs for chronic myeloid leukemia (CML) at the single-cell level. This technology leverages the principle of resonance energy transfer (FRET) with the substrate CrkL of BCR ABL, enabling highly sensitive and quantitative measurement of protein movement and function in living cells. The primary market for Horizon IlluminationLab includes medical institutions and pharmaceutical companies involved in the treatment and research of CML. The business model revolves around providing cutting-edge diagnostic tools that allow for precise drug sensitivity analysis before treatment begins, thereby improving patient outcomes and optimizing therapeutic strategies. Revenue is generated through the sale of bioimaging equipment, licensing of technology, and partnerships with healthcare providers and research institutions.

Keywords: Fluorescent bioimaging, drug efficacy, chronic myeloid leukemia, single-cell analysis, FRET technology, protein movement, quantitative measurement, diagnostic tools, healthcare, pharmaceutical partnerships.